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Summary
Background.  —  Deﬁbrillation  testing  (DT)  is  usually  performed  during  implantable  cardioverter
deﬁbrillator  (ICD)  implantation.
Aims.  —  We  conducted  a  multicentre  prospective  study  to  determine  the  DT  procedures
used in  everyday  practice,  to  compare  the  characteristics  of  patients  with  or  without  DT,
Abbreviations: AF, Atrial ﬁbrillation; DFT, Deﬁbrillation threshold; DT, Deﬁbrillation testing; ICD, Implantable cardioverter deﬁbrillator;
VEF, Left ventricular ejection fraction; NYHA, New York Heart Association; VVI, Single chamber deﬁbrillator.
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and  to  compare  severe  adverse  events  in  these  two  populations  during  implantation  and
follow-up.
Methods.  —  The  LEADER  registry  enrolled  904  patients  included  for  primo-implantation  of  a
single (n  =  261),  dual  (n  =  230)  or  triple  (n  =  429)  deﬁbrillation  system  in  42  French  centres.
Results.  —  Baseline  characteristics  of  patients  (62.0  ±  13.5  years;  88%  men;  primary  indica-
tion 62%)  who  underwent  ventricular  ﬁbrillation  (VF)  induction  (VF  induction  group,  n  =  810)
and those  who  did  not  (untested  group,  n  =  94,  representing  10.4%  of  the  entire  study  pop-
ulation) revealed  that  the  untested  group  were  older  (P  <  0.01),  had  a  lower  left  ventricular
ejection fraction,  a  wider  QRS  complex  and  a  higher  New  York  Heart  Association  class  and  were
more often  implanted  for  primary  prevention  (P  <  0.001  for  all).  The  main  reason  given  for  not
performing  ICD  testing  was  poor  haemodynamic  condition  (59/94).  At  1  year,  the  cumulative
survival rate  was  95%  in  tested  patients  and  85%  in  untested  patients  (P  <  0.001),  mainly  because
of heart  failure  deaths.  There  was  one  sudden  cardiac  death  in  the  VF  induction  group  and  none
in the  untested  group  (P  =  1.000).
Conclusions.  —  In  this  study,  more  than  10%  of  ICD  patients  were  implanted  without  VF  induction.
Untested patients  appeared  to  be  sicker  than  tested  patients,  with  a  more  severe  long-term
outcome, but  without  any  difference  in  mortality  due  to  arrhythmic  events.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Les  tests  de  déﬁbrillation  (DT)  sont  généralement  effectués  lors  de  l’implantation
d’un déﬁbrillateur  automatique  implantable  (DAI).
Objectifs.  —  Cette  étude  prospective  multicentrique  a  été  réalisée  aﬁn  de  :  déterminer  quelles
sont les  procédures  utilisées  pour  réaliser  les  DT  dans  la  « vraie  vie  » ;  comparer  les  caractéris-
tiques des  patients  avec  ou  sans  DT  ;  et  comparer  les  événements  secondaires  graves  entre  ces
deux populations  au  cours  de  l’implantation  et  du  suivi.
Méthodes.  — Dans  le  registre  LEADER,  904  patients  (62,0  ±  13,5  ans  ;  88  %  hommes,  indication
primaire  =  62  %)  ont  été  inclus  dans  le  cadre  d’une  primo-implantation  d’un  système  de  déﬁb-
rillation simple  (n  =  261),  double  (n  =  230)  ou  triple  (n  =  429)  chambre  dans  42  centres  franc¸ais.
Résultats. — Les  caractéristiques  de  base  des  patients  ayant  subi  une  induction  de  FV  (groupe
avec induction  de  FV,  n  =  810)  et  ceux  non  testés  (groupe  non  testé,  n  =  94,  représentant  10,4  %
de l’ensemble  de  la  population  de  l’étude)  a  révélé  que  les  patients  non  testés  étaient  signi-
ﬁcativement  plus  âgés  (p  <  0,01)  et  avait  une  FEVG  inférieure,  un  QRS  plus  large,  une  classe
NYHA supérieure  et  ont  été  plus  souvent  implantés  pour  une  indication  primaire  (p  <  0,001  pour
tous). La  principale  raison  rapportée  pour  ne  pas  effectuer  les  tests  de  déﬁbrillation  était  un
mauvais état  hémodynamique  (59/94).  Après  1  an,  le  taux  de  survie  cumulé  était  de  95  %  chez
les patients  testés  contre  85  %  chez  les  patients  non  testés  (p  <  0,001),  principalement  suite  à
des décès  pour  insufﬁsance  cardiaque.  Il  n’y  a  eu  qu’une  seule  mort  subite  dans  le  groupe  avec
induction de  FV  et  aucune  dans  le  groupe  non  testé  (p  =  1,000).
Conclusions.  —  Dans  cette  étude  multicentrique,  >  10  %  des  patients  sont  implantés  avec  un  DAI
sans induction  de  VF.  Les  patients  non-testés  semblent  être  de  condition  plus  précaire  que
les patients  testés  avec  un  résultat  à  long  terme  plus  péjoratif,  mais  sans  différence  dans  la
mortalité due  à  des  événements  rythmiques.
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Background
During  implantable  cardioverter  deﬁbrillator  (ICD)  implanta-
tion  procedures,  it  is  common  practice  to  induce  ventricular
ﬁbrillation  (VF)  to  assess  the  reliability  of  the  device  for  VF
detection  and  termination.  Until  the  early  2000s,  patients
underwent  several  VF  inductions,  usually  using  a  step-down
protocol  with  decreasing  energies,  to  determine  the  deﬁ-
brillation  threshold  (DFT)  [1,2].  Today,  DFT  determination
is  rarely  performed,  but  a  ≥  10  J  safety  margin  for  efﬁ-
cient  deﬁbrillation  is  required  [3—5].  DFT  determination  is,
however,  still  considered  as  a  critical  part  of  a  successful
implantation  procedure,  even  though  Swerdlow  et  al.  [6]
s
fs  droits  réservés.
eported,  from  a  review  of  the  literature,  that  in  25—50%
f  ICD  recipients,  testing  could  not  be  identiﬁed  as  either
ritical  or  contraindicated.
Although  the  risk  associated  with  deﬁbrillation  test-
ng  (DT)  is  low  [6—8],  VF  induction  is  not  a risk-free
rocedure.  Serious  complications  may  occur  such  as  tran-
ient  ischaemic  attack,  cardiopulmonary  arrest,  cardiogenic
hock  and  embolic  events,  especially  in  the  case  of  atrial
brillation  (AF),  and  even  death  (<1%)  [7,9,10].  These
omplications  may  be  a  consequence  of  VF  induction  per
e  and/or  the  difﬁculty  in  deﬁbrillating  the  heart.
Physicians  have  recently  focused  on  the  usefulness  of  DT,
or  several  reasons:  the  increasing  number  of  ICDs  implanted
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10];  changes  in  ICD  technology  resulting  in  lower  DFTs
11,12];  availability  of  high  energy  devices;  and  the  spread
f  cardiac  resynchronization  therapy  with  ICD  backup  in
atients  who  may  not  tolerate  VF  induction  exhibiting  DT
omplications  [13].  There  is  an  increasing  body  of  literature
n  the  outcome  of  patients  implanted  without  DT  [9,13—15].
ost  of  these  studies  are  focused  on  the  immediate  out-
ome  of  DT  with  little  or  no  data  on  short-  or  long-term
ollow-up.  The  main  objectives  of  the  LEADER  registry  were
o  determine  DT  procedures  in  everyday  clinical  practice,  to
ompare  the  characteristics  of  patients  with  or  without  VF
nduction,  and  to  compare  severe  adverse  events  between
hese  two  populations  during  the  implantation  procedure
nd  at  1-year  follow-up.
ethods
tudy population
ll  patients  received  an  ENDOTAK  RELIANCE®
Guidant/Boston  Scientiﬁc,  Natick,  MA,  USA)  active  or
assive  ICD  lead,  with  a  single  or  dual  coil,  connected  to  a
ingle  dual  ICD  (Vitality® ICD)  or  a  deﬁbrillator  with  cardiac
esynchronization  therapy/triple  chamber  ICD  (RENEWAL®;
uidant/Boston  Scientiﬁc,  Natick,  MA,  USA).  The  patients
ncluded  in  this  trial  were  ≥  18  years  of  age  and  underwent
 ﬁrst  ICD  implantation  for  primary  or  secondary  prevention
ndications  according  to  the  French  and  European  Society
f  Cardiology  guidelines  [16,17].
This  observational  study  was  approved  by  the  French  Min-
stry  of  Scientiﬁc  Research  and  the  French  Privacy  Authority.
ritten  informed  consent  to  participate  in  the  registry  was
btained  from  each  patient.  The  study  complied  with  the
rinciples  of  the  1975  Declaration  of  Helsinki.
ata collection and patient follow-up
aseline  and  clinical  data  were  collected  at  inclu-
ion,  as  were  data  on  procedural  characteristics,  device
mplantation-related  adverse  events  and  device  program-
ing  at  the  time  of  hospital  discharge.  Patients  were
ubsequently  divided  in  two  groups:  patients  who  underwent
F  induction  at  implantation  or  before  hospital  discharge
VF  induction  group);  and  patients  who  did  not  undergo  VF
nduction  (untested  group).
The  patients  were  followed  up  at  3—6  months  and  at
2  months  after  the  implantation.  DT  procedures  were
eft  to  the  investigator’s  discretion,  but  reasons  for  not
erforming  a  VF  induction  at  implantation  were  recorded
rospectively.  ICD  programming  parameters  for  tachycardia
r  bradycardia  were  also  left  at  the  investigator’s  discre-
ion.
tatistical methods
tatistical  analysis  was  performed  using  SAS  V9.2  (SAS  Insti-
ute,  Cary,  NC,  USA).  Descriptive  statistics  were  used  to
nalyse  the  data.  The  level  for  statistical  signiﬁcance  was
eﬁned  as  P  <  0.05.  For  continuous  variables,  sample  size,
ean,  standard  deviation,  minimum,  median,  ﬁrst  quartile,
hird  quartile,  maximum  and  number  of  missing  data  were
t
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eported.  For  discrete  variables,  numbers  of  missing  data,
requency  and  percentage  by  modality  were  collected.  For
ariables  with  the  modality  ‘‘unavailable’’  or  ‘‘not  done’’,
ercentages  were  calculated  by  exclusion  of  missing  val-
es  and  non-informative  categories  (e.g.  ‘‘unavailable’’  or
‘not  done’’).  For  comparison  tests  between  subgroups,  the
ollowing  analyses  were  used:  variance  analysis  for  quan-
itative  variables  (or  analysis  of  variance  on  ranks  when
ormality  assumptions  were  not  met);  and  the  chi-squared
est  (or  Fisher’s  exact  test  when  the  expected  number  in  at
east  one  cell  is  ≤  5)  for  dichotomous  variables.
Numbers  of  events  per  patient  were  compared  using
ank  ANOVA  analysis.  Time-to-event  analyses  were  con-
ucted  using  Kaplan—Meier  rates  to  estimate  the  percentage
f  patients  with  no  events  at  speciﬁed  time  inter-
als.
esults
tudy population
atient  characteristics  are  given  in  Table  1.  In  total,  904
atients  were  enrolled  in  42  centres,  representing  half  of
ll  French  ICD  implantation  centres.  Primary  prevention
mplantation  was  performed  in  560  patients  (62%).  Baseline
haracteristics  of  patients  in  the  VF  induction  group  (n  = 810)
nd  the  untested  group  (n  =  94)  revealed  that  untested
atients  were  older  (P  <  0.01),  had  a  lower  left  ventricu-
ar  ejection  fraction  (LVEF),  a  wider  QRS  complex  and  a
igher  New  York  Heart  Association  (NYHA)  class  and  were
ore  often  implanted  for  primary  prevention  (P  <  0.001  for
ll),  (Table  1).  The  therapy  regimen  was  identical  in  the
wo  groups  except  for  beta-blocker  therapy,  which  was  more
ommon  in  the  VF  induction  group  (74.6%  versus  63.8%;
 =  0.035).  The  rate  of  untested  patients  remained  stable
uring  the  course  of  the  study,  representing  10.4%  of  the
ntire  study  population.  The  mean  follow-up  was  10.5  ±  5.1
onths  (0—15  months).
rocedural testing and early complications
≤30 days)
n  the  810  patients  in  the  VF  induction  group,  four  could
ot  be  induced  despite  repeated  inductions.  Among  the
06  remaining  patients,  74.8%  (603/806)  underwent  one,
1%  underwent  two  (169/806)  and  4.2%  (34/806)  under-
ent  three  or  more  VF  inductions,  mainly  due  to  routine
edical  practice.  In  total,  92.2%  (743/806)  of  the  806  suc-
essfully  induced  patients  had  a  safety  margin  ≥  10  J.  Such
 safety  margin  could  not  be  obtained  in  60/63  patients
espite  polarity  shock  reversal  (n  =  45)  and/or  right  ven-
ricle  lead  repositioning  (n  =  18)  and/or  disconnection  of
he  proximal  coil  (n  =  2),  whereas  a  single  coil  lead  was
eplaced  by  a  dual  coil  lead  in  one  patient  and  a  high  energy
evice  was  implanted  in  two  patients  (1.1  changes/patient).
o  modiﬁcation  was  attempted  in  the  remaining  three
atients  (investigator’s  decision).  Among  the  94  patients  in
he  untested  group,  the  main  reason  given  by  the  implant-
ng  physician  for  not  performing  DT  was  poor  haemodynamic
ondition  (59/94).  Other  reasons  included  primary  ICD  indi-
ation  (n  =  11),  AF  (n  =  9),  lack  of  available  anaesthesiologist
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Table  1  Baseline  characteristics  of  patients  entered  in  the  LEADER  registry.
Total  (n  =  904)  VF  induction  group  (n  =  810)  Untested  group  (n  =  94)  Pa
Men  85.4  85.8  81.9  0.35
Age  (years)  62.1  ±  12.8  61.7  ±  12.8  65.4  ±  11.6  <0.01
LVEF  (%)  0.32  ±  0.13  0.32  ±  0.13  0.26  ±  0.08  <0.001
NYHA  class  III  +  IV  45.7  42.5  73.1  <0.001
QRS  complex  (ms)  127.6  ±  38.0  125.4  ±  37.5  146.2  ±  37.5  <0.001
Cardiomyopathy
Ischaemic  562  (62.2) 503  (62.1) 59  (62.8) 1.000
Dilated  232  (25.7) 199  (24.6) 33  (35.1) 0.033
Other  disorders  91  (10.1)  89  (11.0)  2  (2.1)  <0.01
None  19  (2.1)  19  (2.3)  0  (0)  0.25
Permanent  AF  90  (10)  74  (9.2)  16  (17.4)  0.026
Primary  prevention  560  (62)  486  (60)  74  (79.6)  <0.001
Devices
VVI  261  (28.6)  244  (30.1)  13  (13.4)  <0.001
DDD  230  (25)  215  (26.1)  15  (15.5)  0.025
CRT-D
Total  429  (47)  360  (43.7)  69  (71.1)  <0.001
High  energy  only  97  (10.5)  73  (8.9)  24  (24.7)  0.029
Drug  therapy
Beta-blocker  664  (73.5)  604  (74.6)  60  (63.8)  0.035
Amiodarone  246  (27.2)  218  (26.9)  28  (29.8)  0.54
ACE  inhibitor/ARB  642  (71.0)  570  (70.4)  72  (76.6)  0.23
Antiplatelet  agent  394  (43.6)  354  (43.7)  40  (42.6)  0.91
Anticoagulant  261  (28.9)  234  (28.9)  27  (28.7)  1.00
Data are mean ± standard deviation, % or number (%). ACE: angiotensin-converting enzyme; AF: atrial ﬁbrillation; ARB: angiotensin
II receptor blocker; CRT-D: deﬁbrillator with cardiac resynchronization therapy/triple chamber ICD; DDD: dual chamber deﬁbrillator;
LVEF: left ventricular ejection fraction; NYHA: New York heart association; VF: ventricular ﬁbrillation; VVI: single chamber deﬁbrillator.
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(n  =  3),  pacemaker  dependency  (n  =  3),  other  cardiac  rea-
sons  (n  =  2)  and  tamponade  at  implantation  (n  =  1).  The
reason  for  not  performing  DT  could  not  be  obtained  in  six
patients.
Early  (≤  30  days  postimplantation)  fatal  and  non-fatal
serious  complications  occurred  in  68  patients.  Eight  patients
died  within  a  month  of  implantation,  seven  in  the  VF  induc-
tion  group  (0.9%)  and  one  in  the  untested  group  (1.1%;
P  =  0.59)  (Table  2).  In  the  VF  induction  group,  there  were  four
cardiac  deaths  (0.5%)  (heart  failure  in  two  patients,  9  and  18
days  after  implant;  one  myocardial  infarction  at  day  6;  one
electromechanical  dissociation  at  day  12)  and  three  non-
cardiac  deaths  (0.4%).  One  patient  in  the  untested  group
experienced  cardiogenic  shock  the  day  after  implantation
and  died  at  day  8.
Non-fatal  serious  adverse  events  (i.e.  new  or  prolonged
hospitalization  or  leading  to  a  new  intervention)  occurred
in  60  patients  (Table  3).  Sixty-two  complications  occurred
in  52  VF-induction  patients  (6.8%)  and  nine  complications  in
eight  patients  in  the  untested  group  (10.1%;  P  =  0.26).
Complications during long-term follow-up (>30
days)During  long-term  follow-up,  54  patients  died,  40  in  the  VF
induction  group  (4.9%)  and  14  in  the  untested  group  (14.9%)
(P  <  0.001).  Detailed  information  is  given  in  Table  2.  There
g
n
T
Pas  a  sixfold  increase  in  heart  failure  deaths  in  the  untested
roup  (9.6%)  compared  with  the  VF  induction  group  (1.6%;
 <  0.001).  One  sudden  cardiac  death  occurred  in  the  VF
nduction  group  and  none  in  the  untested  group  (P  =  1.000).
Non-fatal  serious  adverse  events  occurred  in  180  patients
Table  3):  218  complications  were  reported  in  158  VF  induc-
ion  group  patients  (20.7%)  and  30  complications  in  22
ntested  group  patients  (27.8%;  P  =  0.15).  There  were  no
ifferences  in  the  rates  of  device-related  complications,
rrhythmic  complications  (appropriate  or  inappropriate
herapies)  and  device-related  infections  between  the  two
roups.  Non-cardiac  events  were  more  frequent  in  the
ntested  group  (P  <  0.01)  (Table  3).
atient survival
t  1 year,  the  cumulative  survival  rate  was  95%  in  the  VF
nduction  group  and  85%  in  the  untested  group  (P  <  0.001;
ig.  1);  the  cumulative  rate  of  survival  free  of  hospitalization
as  73%  in  the  VF  induction  group  and  58%  in  the  untested
roup  (P  <  0.001;  Fig.  2).  In  the  VF  induction  group,  the  sub-
et  of  patients  with  a  safety  margin  <10  J  exhibited  a  higher
otal  mortality  than  patients  with  an  adequate  safety  mar-
in  (14.3%  versus  5.1%;  P  =  0.008),  due  to  a  higher  rate  of
on-cardiac  death  with  no  difference  in  arrhythmic  death.
he  rates  of  unknown  causes  of  death  (1.6%  versus  0.7%;
 =  0.39)  did  not  differ  between  groups.
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Table  2  Causes  of  death.
Total  (n  =  904)  VF  induction  group  (n  =  810)  Untested  group  (n  =  94)  Pa
Early  deaths  (≤30  days)
Heart  failure  3  (0.3)  2  (0.2)  1  (1.1)  0.28
Myocardial  infarction  1  (0.1)  1  (0.1)  0  (0)  1.00
Electromechanical  dissociation  1  (0.1)  1  (0.1)  0  (0)  1.00
Non-cardiac  3  (0.3)  3  (0.4)  0  (0)  1.00
Subtotal  (early  deaths) 8  (0.9) 7  (0.9)  1  (1.1)  0.59
Late  deaths  (>30  days)
Heart  failure 22  (2.4) 13  (1.6) 9  (9.6) <0.001
Myocardial  infarction 1  (0.1) 1  (0.1) 0  (0) 1.00
Sudden  cardiac  death  1  (0.1)  1  (0.1)  0  (0)  1.00
Arrhythmic  3  (0.3)  3  (0.4)  0  (0)  1.00
Electromechanical  dissociation  2  (0.2)  1  (0.1)  1  (1.1)  0.20
Non-cardiac  18  (2.0)  15  (1.9)  3  (3.2)  0.42
Unknown  7  (0.8) 6  (0.7) 1  (1.1) 0.54
Subtotal  (late  deaths) 54  (6.0) 40  (4.9) 14  (14.9) 0.001
Total  62  (6.9)  47  (5.8)  15  (16.0)  <0.001
Data are number (%). VF: ventricular ﬁbrillation.
a Fisher’s exact test; VF induction group versus untested group.
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Figure 2. Kaplan—Meier analysis of survival free from hospital-
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the VF induction group versus the untested group. VF: ventricular
brillation.
iscussion
his  prospective  registry,  involving  patients  representative
f  ‘‘real  life’’  DT  during  ICD  implantation  in  France,  reveals
hat  although  DT  is  still  considered  the  standard  of  care
t  implantation  [3],  approximately  10%  of  patients  do  not
ndergo  VF  induction  during  routine  ﬁrst  ICD  implantation.
ntested  patients  appear  to  have  more  comorbidities  than
ested  patients;  they  also  exhibit  a  worse  outcome  during
ollow-up,  with  a  higher  rate  of  hospitalizations  and  a  15%
I
n
Ization in the VF induction group versus the untested group. VF:
entricular ﬁbrillation.
-year  mortality  versus  5%  in  tested  patients,  although  death
n  untested  patients  was  mainly  related  to  heart  failure  with
o  signiﬁcant  difference  for  arrhythmic  deaths.  There  were
o  life-threatening  complications  related  to  DT  at  implan-
ation.
Although  the  rate  of  complications  during  ICD  implanta-
ion  is  low,  it  is  not  negligible.  Birnie  et  al.  [8]  reported
CD  testing  complications  in  19,067  patients  undergoing  de
ovo  implantation  or  device  replacements  in  all  21  adult
CD  Canadian  centres  from  January  2000  to  September  2006.
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Table  3  Overall  complications  excluding  death.a
Type  of  complication  VF  induction  group  (n  =  763)  Untested  group  (n  =  79)  Pb
Early  complications  (≤30  days)
Technical  issues
Lead  or  connection  problems  15  2  0.66
DT  issues  (device  upgrade)  5  0  1.00
Procedure  related
Tamponade,  pneumothorax,  pocket/haematoma 10  2  0.31
Arrhythmic  issues
Inappropriate  or  appropriate  therapies,
arrhythmic  storm,  atrial/ventricular  disorders
15  0  0.62
Cardiac  complications
Heart  failure  4  3  0.072
Myocardial  infarction  5  1  0.45
Other  4  0  1.00
Other
Non-cardiac  events 4  1  0.33
Subtotal  (early) 62  (52  patients) 9  (8  patients) 0.26
Late  complications  (>30  days)
Infection
System  explant  7  0  1.00
Pocket/haematoma  9  1  1.00
Other  device  issues
Lead  or  connection  problems  29  4  0.32
Arrhythmic  issues
VT  below  rate  detection,  inappropriate  or
appropriate  therapy,  device  reprogramming,
arrhythmic  storm
46 3  1.00
Cardiac  complications
Heart  failure  47  2  0.57
Myocardial  infarction  12  1  1.00
Other  26  8  0.19
Other
Non-cardiac  events  42  11  0.01
Subtotal  (late)  218  (158  patients)  30  (22  patients)  0.15
Total  (Early  +  late  complications)  280  (193  patients)  39  (26  patients)  0.14
Data are numbers of complications. DT: deﬁbrillation testing; VF: ventricular ﬁbrillation; VT: ventricular tachycardia.
a Only serious adverse events occurring in surviving patients are mentioned in this table.
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There  were  0.016%  (3/19,067)  DT-related  deaths.  The  inci-
dence  of  cerebrovascular  accident  or  transient  ischaemic
attack  was  0.026%  (5/19,067).  Other  severe  complications
included  prolonged  resuscitation  during  ICD  testing  in  27
patients  (0.14%  incidence),  with  two  patients  having  sig-
niﬁcant  sequelae.  In  the  present  study,  VF  induction  was
not  associated  with  an  increased  rate  of  complications
at  implantation  and  no  deaths  or  severe  complications
occurred  during  testing,  but  it  must  be  emphasized  that
the  number  of  patients  undergoing  testing  was  more
than  20  times  lower  than  in  the  study  by  Birnie  et  al.
[8].
There  was  no  difference  in  mortality  between  the  two
groups  during  the  ﬁrst  month,  whereas  mortality  was  sig-
niﬁcantly  higher  in  untested  patients  during  long-term
follow-up  (14.9%  versus  4.9%;  P  <  0.001),  (Table  2).  This  is
in  agreement  with  previous  retrospective  studies,  which
reported  that  lack  of  testing  at  the  time  of  ICD  implantation
was  associated  with  higher  mortality  during  follow-up.  For
t
i
u
axample,  Pires  et  al.  [18]  reported  in  a  retrospective  mono-
entre  study  the  outcome  of  835  patients  according  to  the
T  performed  at  implantation.  In  this  study,  129  patients
ad  real  deﬁbrillation  threshold  determinations,  whereas
03  had  limited  deﬁbrillation  safety  margin  testing  and  the
emaining  203  had  no  DT.  During  follow-up,  the  success  rates
f  the  ﬁrst  delivered  shock  for  spontaneous  VT/VF  events
ere  identical  in  the  three  groups  (>90%)  and  the  second
hock  terminated  the  remaining  episodes  in  all  three  groups.
udden-death-free-survival  rates  were  similar  in  the  three
roups.  The  overall  long-term  survival  rate  was,  however,
igniﬁcantly  lower  in  the  untested  group  compared  with  that
n  the  DFT  group  or  the  safety-margin  testing  group  (58%
s  74%  and  69%,  respectively;  P  <  0.0005).  The  lack  of  ICD
esting  was  an  independent  predictor  of  overall  mortality  in
he  multivariable  analysis.  In  the  present  study,  the  differ-
ng  cumulative  survival  rates  of  95%  in  tested  versus  85%  in
ntested  patients  (P  <  0.001)  mainly  related  to  heart  failure
nd  not  to  arrhythmic  deaths.
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In  this  observational  study,  the  main  reason  given  by  the
mplanting  physician  for  not  performing  a  VF  induction  was
oor  haemodynamic  condition.  Untested  patients  appeared
o  be  sicker  than  tested  patients,  with  a  signiﬁcantly  lower
VEF,  a  wider  QRS  complex,  a  higher  NYHA  class  and  a  higher
ncidence  of  cardiac  resynchronization  therapy  implanta-
ion.  This  tendency  not  to  test  the  more  severe  patients
as  also  been  reported  by  others  [8,9,18]. In  the  study  by
ires  et  al.  [18],  the  reasons  for  not  performing  a  deﬁbrilla-
ion  test  were  inadequate  anticoagulation  at  implantation  or
nown  cavity  thrombus  in  almost  half  of  the  patients  (49.8%)
nd  intraoperative  hypotension  requiring  supporting  therapy
n  around  20%  of  cases.  In  our  study,  the  main  reasons  given
or  not  performing  DT  were  poor  haemodynamic  conditions
ith  intraoperative  hypotension  in  almost  two-thirds  of  the
atients  and  primary  indication  or  lack  of  adequate  anti-
oagulation  for  approximately  20%  of  the  patients.  These
iscrepancies  may  largely  be  explained  by  the  difference  in
he  period  of  inclusion,  with  implantations  mainly  due  to
econdary  prevention  in  the  study  by  Pires  et  al.  [18]  and
ostly  primary  prevention  indications  in  our  study  (approxi-
ately  two-thirds  of  the  patients).  Although  the  conclusions
f  the  Canadian  experience  are  drawn  from  a  registry  with
ll  the  limitations  of  retrospective  registries,  Birnie  et  al.
8]  reported  that  the  decision  not  to  perform  a  DT  was  not
andom,  with  a  tendency  not  to  test  the  sickest  patients.
imilar  observations  were  reported  in  the  recent  Ontario  ICD
egistry  [9],  with  only  58%  of  patients  undergoing  a  deﬁbril-
ation  test  at  ﬁrst  implantation  or  device  replacement.  In
his  registry,  Healey  et  al.  suggested  that  physicians  have
 bias  against  testing  patients  with  an  LVEF  <  20%  and  those
ith  AF,  who  are  at  increased  risk  of  embolic  complications,
articularly  if  AF  is  converted  to  sinus  rhythm  during  test-
ng.  The  present  study,  carried  out  in  everyday  medical
ractice  during  ICD  implantation,  was  associated  with  a
igher  incidence  of  death  during  long-term  follow-up  of
ntested  patients  who  appeared  to  be  sicker  than  tested
atients;  these  ﬁndings  are  in  agreement  with  these  previ-
us  statements.
tudy limitations
atients  included  in  the  present  study  were  not  consecutive,
s  the  decision  to  include  a  patient  receiving  a  de  novo  ICD
as  left  to  the  investigator’s  discretion.  In  this  prospective
tudy,  data  were  collected  on  paper  and  some  missing  data
ould  not  be  obtained  despite  extensive  repeated  requests
o  the  investigators.
onclusion
rom  this  large  prospective  study,  it  appears  that  more  than
0%  of  ICD  patients  are  implanted  without  DT.  Untested
atients  appear  to  be  sicker  than  tested  patients  with  a
ore  severe  long-term  outcome  and  no  difference  in  mortal-ty  due  to  arrhythmic  events.  Prospective  randomized  trials
ith  longer  follow-up  are  mandatory  to  determine  whether
T  is  still  required  and  how  it  should  be  achieved,  during
CD  implantation.
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